<HashMap><database>GEO</database><file_versions><headers><Content-Type>application/xml</Content-Type></headers><body><files><Other>ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE337nnn/GSE337837/</Other></files><type>primary</type></body><statusCode>OK</statusCode><statusCodeValue>200</statusCodeValue></file_versions><scores/><additional><omics_type>Transcriptomics</omics_type><species>Mus musculus</species><gds_type>Expression profiling by high throughput sequencing</gds_type><full_dataset_link>https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE337837</full_dataset_link><repository>GEO</repository><entry_type>GSE</entry_type></additional><is_claimable>false</is_claimable><name>Macrophage-Derived IL-18 Drives M1 Polarization via IFN-γ/JAK1-STAT1 Axis to Promote Myocardial Injury in Fulminant Myocarditis</name><description>Fulminant myocarditis (FM) is a rapid, severe form of myocarditis requiring urgent mechanistic insight. While anti-interleukin-18 (IL-18) antibodies show promise in other inflammatory diseases, IL-18’s role in FM remains unknown. Here, we found that plasma IL-18 levels in FM patients negatively correlated with ejection fraction and positively with NT-proBNP. Elevated IL-18 was confirmed in a coxsackievirus B3 (CVB3)-induced murine FM model, with macrophages identified as the primary cellular source. Exogenous IL-18 promoted M1 macrophage polarization without affecting cardiomyocytes or fibroblasts. Neutralizing IL-18 antibodies (IL-18nAbs) suppressed M1 polarization and chemokine secretion in vitro, and improved survival, reduced myocardial M1 infiltration, and preserved cardiac function in vivo. Mechanistically, IL-18 activated the JAK1-STAT1 axis in macrophages; STAT1 silencing abrogated IL-18-driven M1 polarization. IL-18 also induced IFN-γ, and IFN-γ neutralization blocked Stat1 and Nos2 upregulation. Myeloid-specific IL-18R1 deletion alleviated CVB3-induced cardiac dysfunction and inflammation. Collectively, IL-18, primarily from macrophages, drives FM progression via JAK1-STAT1, representing a key pathogenic factor and therapeutic target.</description><dates><publication>2026/07/08</publication></dates><accession>GSE337837</accession><cross_references><GSM>GSM9861239</GSM><GSM>GSM9861238</GSM><GSM>GSM9861240</GSM><GSM>GSM9861243</GSM><GSM>GSM9861242</GSM><GSM>GSM9861241</GSM><GPL>18480</GPL><GSE>337837</GSE><taxon>Mus musculus</taxon></cross_references></HashMap>